Preventing type 2 diabetes mellitus: a call for personalized intervention.

In parallel with the rising prevalence of obesity worldwide, especially in younger people, there has been a dramatic increase in recent decades in the incidence and prevalence of metabolic consequences of obesity, in particular prediabetes and type 2 diabetes mellitus (DM2). Although approximately one-third of US adults now meet one or more diagnostic criteria for prediabetes, only a minority of those so identified as being at risk for DM2 actually progress to diabetes, and some may regress to normal status. Given the uncertain prognosis of prediabetes, it is not clear who is most likely to benefit from lifestyle change or medication interventions that are known to reduce DM2 risk. We review the many factors known to influence risk of developing DM2 and summarize treatment trials demonstrating the possibility of preventing DM2. Applying the concepts of personalized medicine and the potential of "big data" approaches to analysis of massive amounts of routinely gathered clinical and laboratory data from large populations, we call for the development of tools to more precisely estimate individual risk of DM2.

[1]  G. Nichols,et al.  Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. , 2008, The American journal of medicine.

[2]  A. Chetrit,et al.  Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up , 2012, Diabetes/metabolism research and reviews.

[3]  O. Ober Diabetes Prevention Program , 2012 .

[4]  Bernd Richter,et al.  Exercise or exercise and diet for preventing type 2 diabetes mellitus. , 2008, The Cochrane database of systematic reviews.

[5]  Heidemarie Keller,et al.  Absolute Cardiovascular Disease Risk and Shared Decision Making in Primary Care: A Randomized Controlled Trial , 2008, The Annals of Family Medicine.

[6]  Jaakko Tuomilehto,et al.  Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[7]  D. Williamson,et al.  Pretreatment, Psychological, and Behavioral Predictors of Weight Outcomes Among Lifestyle Intervention Participants in the Diabetes Prevention Program (DPP) , 2012, Diabetes Care.

[8]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[9]  K. Watson,et al.  Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.

[10]  Ralph B D'Agostino,et al.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.

[11]  Rui Li,et al.  Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. , 2012, American journal of preventive medicine.

[12]  A. Rissanen,et al.  Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. , 2000, Archives of internal medicine.

[13]  Karel G M Moons,et al.  Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study , 2012, BMJ : British Medical Journal.

[14]  J. Shaw,et al.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.

[15]  Kim,et al.  Big Data in Healthcare Hype and Hope , 2013 .

[16]  D. Williamson,et al.  How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? , 2012, Health Affairs.

[17]  Ping Zhang,et al.  Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review , 2010, Diabetes Care.

[18]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[19]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[20]  P. Sorlie,et al.  Lifestyle Factors and Risk for New-Onset Diabetes , 2011, Annals of Internal Medicine.

[21]  R. Ratner The Imperative to Prevent Diabetes , 2012, Diabetes Care.

[22]  Peter Almgren,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2008, The New England journal of medicine.

[23]  B. Spring,et al.  Integrating technology into standard weight loss treatment: a randomized controlled trial. , 2013, JAMA internal medicine.

[24]  Jay R. Desai,et al.  Construction of a Multisite DataLink Using Electronic Health Records for the Identification, Surveillance, Prevention, and Management of Diabetes Mellitus: The SUPREME-DM Project , 2012, Preventing chronic disease.

[25]  L. Barker,et al.  A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. , 2012, Health affairs.

[26]  Makoto Watanabe,et al.  Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. , 2011, Archives of internal medicine.

[27]  Terho Lehtimäki,et al.  Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin Resistance in Young Adults , 2013, Diabetes Care.

[28]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[29]  R. Hayward,et al.  PREVALENCE, DIAGNOSIS, AND TREATMENT OF IMPAIRED FASTING GLUCOSE AND IMPAIRED GLUCOSE TOLERANCE , 2010 .

[30]  R. Muniyappa,et al.  The diabetes prevention program , 2003, Current diabetes reports.

[31]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[32]  S. Wild,et al.  Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes , 2012, Diabetes Care.

[33]  Simon J. Griffin,et al.  Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes , 2011, Epidemiologic reviews.

[34]  D. Pereg,et al.  Normal fasting plasma glucose levels and type 2 diabetes in young men. , 2005, The New England journal of medicine.

[35]  M. Schulze Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[36]  P. Lavori,et al.  Translating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss into Primary Care a Randomized Trial , 2022 .

[37]  Harald Rinde,et al.  Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score , 2011, Journal of medical economics.

[38]  K. Fujihara,et al.  Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA1c and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4) , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[39]  T. Hansen,et al.  Validation of a Multimarker Model for Assessing Risk of Type 2 Diabetes from a Five-Year Prospective Study of 6784 Danish People (Inter99) , 2009, Journal of diabetes science and technology.

[40]  Lawrence Joseph,et al.  Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. , 2007, Archives of internal medicine.

[41]  Nicola J Cooper,et al.  Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[42]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[43]  Trisha Greenhalgh,et al.  Risk models and scores for type 2 diabetes: systematic review , 2011, BMJ : British Medical Journal.

[44]  G. Collins,et al.  Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting , 2011, BMC medicine.

[45]  W. Rathmann,et al.  Immunological and Cardiometabolic Risk Factors in the Prediction of Type 2 Diabetes and Coronary Events: MONICA/KORA Augsburg Case-Cohort Study , 2011, PloS one.

[46]  A. Spiegel,et al.  'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention: can it fulfill its promise? , 2012, Health affairs.

[47]  Wolfgang Rathmann,et al.  Prediabetes: a high-risk state for diabetes development , 2012, The Lancet.

[48]  S. Fowler,et al.  The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[49]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[50]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[51]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[52]  R. D'Agostino,et al.  Genotype score in addition to common risk factors for prediction of type 2 diabetes. , 2008, The New England journal of medicine.

[53]  G. Nichols,et al.  Validating the Framingham Offspring Study equations for predicting incident diabetes mellitus. , 2008, The American journal of managed care.

[54]  R. DeFronzo,et al.  Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. , 2011, The American journal of cardiology.

[55]  C. Bouchard,et al.  Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. , 2012, The New England journal of medicine.

[56]  N. Rishe,et al.  Metabolic Profiling in Personalized Medicine: Bridging the Gap between Knowledge and Clinical Practice in Type 2 Diabetes Identifying Asymptomatic Subjects at Risk of Developing Dm2 Predictors of Cardiovascular Complications in Dm2 Patients Conclusion & Future Perspective , 2022 .

[57]  Tianxi Cai,et al.  Joint Effects of Common Genetic Variants on the Risk for Type 2 Diabetes in U.S. Men and Women of European Ancestry , 2009, Annals of Internal Medicine.

[58]  Ping Zhang,et al.  The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention , 2012, Diabetes Care.

[59]  S. Haffner,et al.  Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. , 2009, Annals of epidemiology.

[60]  M. McCarthy,et al.  The Genetic and Epigenetic Basis of Type 2 Diabetes and Obesity , 2012, Clinical pharmacology and therapeutics.